Form 4: Arcutis Biotherapeutics Director Howard G. Welgus Sells 10,000 Shares Under 10b5-1 Trading Plan

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) at an average price of $12.71 on February 3, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On February 3, 2025, Howard G. Welgus, a director of Arcutis Biotherapeutics, sold 10,000 shares of common stock.
• The sale was executed under a 10b5-1 trading plan adopted on March 5, 2024, with a plan end date of May 30, 2025.
• The shares were sold at a weighted average price of $12.71, with individual transactions ranging from $12.56 to $13.02.
• Following the transaction, Welgus directly owns 141,944 shares of Arcutis Biotherapeutics.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each respective price within the range set forth in the footnote, upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned, especially when executed under a 10b5-1 trading plan. These plans allow insiders to sell shares over a period of time without being accused of trading on non-public information.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Howard G. Welgus, Form 4, 10b5-1 trading plan, stock sale, director, insider trading